Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 153Melanoma 133Lymphoma 124Prostatic Neoplasms 123Carcinoma, Non-Small-Cell Lung 113Multiple Myeloma 106Carcinoma, Renal Cell 92Ovarian Neoplasms 88Leukemia, Myeloid, Acute 83Sarcoma 82Lung Neoplasms 80Leukemia, Lymphocytic, Chronic, B-Cell 80Leukemia 79Colorectal Neoplasms 79Colonic Neoplasms 74Rectal Neoplasms 71Lymphoma, Non-Hodgkin 69Pancreatic Neoplasms 68Carcinoma, Ovarian Epithelial 66Neoplasms 65Lymphoma, Large B-Cell, Diffuse 65Brain Neoplasms 65Precursor Cell Lymphoblastic Leukemia-Lymphoma 64Lymphoma, Follicular 58Kidney Neoplasms 58Glioblastoma 57Fallopian Tube Neoplasms 54Carcinoma, Hepatocellular 51Lymphoma, Mantle-Cell 50Central Nervous System Neoplasms 50

Interventions

obeticholic acid 1Specimen Handling 1Erlotinib Hydrochloride 1Endoscopy, Gastrointestinal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × NIH × Attenuated familial adenomatous polyposis × Clear all
NCT05223036 2026-05-14

Testing Obeticholic Acid for Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Terminated
15 enrolled
Gastrointestinal

Attenuated familial adenomatous polyposis, Duodenal Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT02961374 2022-07-26

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Gastrointestinal

Attenuated familial adenomatous polyposis, Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡